BioCentury
ARTICLE | Company News

Ligand, Gilead deal

July 25, 2016 7:00 AM UTC

Gilead received non-exclusive, worldwide rights to Ligand’s OmniRat, OmniMouse and OmniFlic human antibody generation platforms. Ligand is eligible to receive undisclosed annual access payments, miles...